Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
You may also be interested in...
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.
Widely viewed as the largest fast-growing pharma market, China can nevertheless be hard to crack for small to mid-sized companies. But a new policy emphasis on quality and affordability are providing a rare opening for those with the right product mix and local partnerships in hand.
China-focused venture goes against tide by acquiring anti-infective assets via multiple deals that will build out its pipeline in an area deprioritized by big pharma.